Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge - Takeaways - MDSpire

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge

  • By

  • Jamila Raja

  • Shuo Li

  • Asal Patterson

  • Steve R. Martinez

  • Perry A. Soriano

  • Xiaowen Wang

  • Peter Y. Z. Jiang

  • July 16, 2026

Share

  • 1

    A 59-year-old male with advanced nodular melanoma developed severe immune-related adverse events (irAEs) after Nivolumab therapy.

  • 2

    Following treatment cessation and resolution of irAEs, the patient was rotated to Ipilimumab and subsequently rechallenged with Nivolumab.

  • 3

    The sequential treatment strategies led to complete remission of melanoma without recurrence of prior irAEs for nearly five years.

  • 4

    The case illustrates the potential for safe reintroduction of immunotherapy after severe toxicity in selected patients.

  • 5

    This approach utilized complementary mechanisms of CTLA-4 and PD-1 blockade to enhance antitumor activity.

Original Source(s)

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge

  • by Jamila Raja, Shuo Li, Asal Patterson, Steve R. Martinez, Perry A. Soriano, Xiaowen Wang, Peter Y. Z. Jiang

  • July 16, 2026

Related Content

Vaccines as treatment for melanoma: an update review

Long-term survival with stereotactic radiosurgery and 100+ cycles of Keytruda in a patient with brain metastases from melanoma

Responsible artificial intelligence in medical imaging: a systematic review